gMendel develops genetic screening technology intended to improve accuracy and reduce cost for detecting genetic disorders. The company’s founders include Chris Kyriakidis and Zoran Velkoski. With the newly announced DKK 9M seed round led by Metavallon VC, gMendel plans to scale its screening services into markets in Latin America, the Middle East, and Africa. The announcement frames the funding as enabling broader deployment of its technology but does not disclose revenue, user metrics, or prior financing. No valuation or detailed financial terms were published in the materials provided.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026